Novel recombinant tissue regenerative protein for collagen synthesis and tissue healing
A novel chimeric recombinant tissue regenerative protein (rTRP) engineered to induce collagen synthesis and accelerate tissue healing. The protein combines the BPC-157 peptide with mTORC1-signaling amino acids and structural building blocks, offering a sustainable, biologically produced alternative for applications in tissue repair, regenerative medicine, and nutritional products.
Overview
This solution is a novel chimeric recombinant tissue regenerative protein (rTRP) designed to upregulate collagen synthesis and accelerate tissue healing. The protein merges the BPC-157 peptide sequence with mTORC1-signaling amino acids (leucine, arginine, methionine) and structural fuel amino acids (glycine, proline, lysine). Upon digestion, the macromolecule triggers a synchronized cascade that liberates BPC-157 to upregulate growth factors driving fibroblast outgrowth and angiogenesis, induces the mTORC1 pathway to stimulate Type I and Type III collagen production, and delivers the raw building blocks required to assemble a high-tensile triple-helix collagen matrix. Beyond collagen synthesis, BPC-157 accelerates tissue healing in tendons, ligaments, and muscle.
Technical specifications
Key features:
- Engineered chimeric recombinant protein combining BPC-157 with mTORC1-signaling and structural amino acids
- Liberates BPC-157 upon digestion to upregulate growth factors (Egr1, TGF-β1, VEGF) and drive fibroblast outgrowth and angiogenesis
- Induces the mTORC1 pathway to trigger Type I and Type III collagen production
- Delivers glycine, proline, and lysine as raw materials for triple-helix collagen matrix assembly
- Produced via recombinant DNA technology in GRAS yeast strains (Pichia pastoris and Saccharomyces cerevisiae) as a sustainable alternative to chemical synthesis
- Designed for extracellular expression using alpha-mating factor secretion signal sequences, with poly-histidine tag purification
Validation to date:
- Demonstrated protective effects of BPC-157 on normal fibroblasts against oxidative stress
- Confirmed generation of BPC-157 and other protein synthesis building blocks after pepsin digestion at pH 1.5 by mass spectrometry
Planned validation:
- Expression and purification evaluation in two GRAS yeast strains with methanol-free promoters and antibiotic-resistance-free plasmids
- Ames test to verify rTRP does not induce mutations
- 90-day oral toxicity study in rodents to establish NOAEL and human dosing metrics
- Amino acid profiling and quantitative mass spectrometry of mouse serum to monitor systemic BPC-157 concentration
- In silico bioinformatic screenings against global databases to confirm rTRP does not mimic known food allergens
Technology readiness level
The technology is in the research and development stage. The company has demonstrated the protective effects of BPC-157 on fibroblasts against oxidative stress and confirmed the generation of BPC-157 and building blocks after simulated digestion. Future validation includes expression and purification in GRAS yeast strains, safety testing (Ames test and 90-day oral toxicity study), and in silico allergenicity screening. The company is seeking co-development partnerships to advance the technology through these validation stages toward commercial application.
About Biocatalist, LLC
Biocatalist is a biotechnology company that has developed a patented process using recombinant DNA technology for the manufacturing of peptides and peptide libraries. The company's platform engineers proteins containing repeated units of specific peptides, which are then expressed in host organisms and purified. This approach provides a sustainable alternative to traditional chemical synthesis, which is known to generate significant amounts of toxic waste. By enabling the biological production of shorter natural peptides, the technology is designed to reduce manufacturing costs by at least five-fold, decrease energy consumption, and shrink required bioreactor sizes by up to 10-fold.
The company’s solutions support ESG objectives for manufacturers in industries such as pharmaceuticals, medicine, and agriculture, including the production of peptide hormones, cancer vaccines, antimicrobial peptides, and bio-pesticides. Biocatalist offers custom services for peptide and peptide library production, as well as specialized mass spectrometry calibration standards. These offerings are designed to help customers improve production efficiency, reduce environmental impact, and achieve greater accuracy in analytical applications. Located in Torrance, California, the company emphasizes the intersection of technical innovation and environmental responsibility in its product and service delivery.
delivered to your inbox.